ArticleCancer2018

Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.

Hagop M Kantarjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.